Olema Pharmaceuticals, Inc. Stock Price, News & Analysis

Olema Oncology (Nasdaq: OLMA) has announced a new clinical trial collaboration with Pfizer (NYSE: PFE) to evaluate the combination of palazestrant and atirmociclib in patients with ER+/HER2- metastatic breast cancer.

The Phase 1b/2 study will assess the safety and combinability of Olema's palazestrant with Pfizer's investigational CDK4 inhibitor atirmociclib in approximately 35 patients, with trial initiation expected in H2 2025. Results will inform a potential pivotal Phase 3 trial in frontline metastatic breast cancer.

Under the agreement, Pfizer will supply atirmociclib while Olema leads the study. Both companies will jointly own clinical data and inventions, with Olema retaining full global commercial rights to palazestrant.

Olema Oncology (NASDAQ:OLMA), a clinical-stage biopharmaceutical company specializing in targeted therapies for breast cancer, has announced its participation in five major investor conferences in September 2025.

The company will present at Citi's Biopharma Back to School Conference (Sept 2), Wells Fargo Healthcare Conference (Sept 3), Cantor Global Healthcare Conference (Sept 4), Morgan Stanley Global Healthcare Conference (Sept 8), and H.C. Wainwright Global Investment Conference (Sept 9). All conferences will take place in Boston and New York, featuring a mix of presentations and fireside chats.

Investors can access live webcasts and recordings through Olema's investor relations website at ir.olema.com.

Olema Oncology (Nasdaq: OLMA) has reported its Q2 2025 financial results and provided key operational updates. The company has selected 90 mg once-daily palazestrant for Part 2 of the OPERA-01 Phase 3 trial and the OPERA-02 Phase 3 trial in combination with ribociclib for breast cancer treatment.

Key financial metrics include $361.9 million in cash and equivalents, and a net loss of $43.8 million for Q2 2025, compared to $30.4 million in Q2 2024. R&D expenses increased to $43.9 million, primarily due to a $10 million milestone payment to Aurigene and increased clinical development activities.

The company expects to present mature data from the Phase 1b/2 study at ESMO 2025, initiate OPERA-02 in Q3 2025, and report OPERA-01 top-line data in H2 2026.

Olema Oncology (Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on breast cancer therapies, has granted stock options to four new employees. The grants total 130,000 shares of common stock with an exercise price of $5.33 per share.

The stock options, approved under the Company's 2022 Inducement Plan, will vest over four years, with 25% vesting after the first year and the remainder vesting monthly over three years. The options have a 10-year term and were granted in accordance with Nasdaq Listing Rule 5635(c)(4).

Olema Oncology (Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on breast cancer therapies, has granted stock options to four new employees. The grants total 154,500 shares of common stock with an exercise price of $4.37 per share.

The stock options, approved under the company's 2022 Inducement Plan, will vest over four years, with 25% vesting in the first year and the remainder vesting monthly over three years. The options have a 10-year term and were granted in accordance with Nasdaq Listing Rule 5635(c)(4).

Olema Pharmaceuticals (NASDAQ: OLMA), a clinical-stage biopharmaceutical company focused on targeted breast cancer therapies, has granted stock options to 11 new employees. The inducement grants, approved under Nasdaq Rule 5635(c)(4), total 322,000 shares with an exercise price of $4.38 per share. The options vest over four years, with 25% vesting after the first year and the remaining 75% vesting monthly over three years. These 10-year term options were granted under Olema's 2022 Inducement Plan as part of the company's employee compensation strategy.

Olema Oncology (NASDAQ: OLMA) has announced the selection of 90 mg once-daily palazestrant dose for two pivotal Phase 3 trials: OPERA-01 and OPERA-02. The FDA-aligned dose selection applies to Part 2 of OPERA-01, a monotherapy trial for second- and third-line ER+/HER2- metastatic breast cancer, and OPERA-02, which combines palazestrant with ribociclib for frontline treatment. The company will present a trial-in-progress poster for OPERA-01 at the upcoming ASCO 2025 Annual Meeting in Chicago. Olema expects to report top-line data from OPERA-01 in 2026 with a potential commercial launch in 2027. The development targets resistance mechanisms in metastatic breast cancer treatment, with palazestrant showing promising results across ESR1 mutant and wild-type ER+/HER2- tumors in both monotherapy and combination settings.

Olema Pharmaceuticals (Nasdaq: OLMA), a clinical-stage biopharmaceutical company specializing in targeted therapies for breast cancer, has announced its participation in two upcoming investor conferences. The company will present at the Jefferies Global Healthcare Conference on June 4, 2025, at 11:40 a.m. ET in New York, and the Goldman Sachs 46th Annual Global Healthcare Conference on June 11, 2025, at 8 a.m. ET in Miami. Both presentations will be in a fireside chat format. Live webcasts and recordings will be accessible through Olema's investor relations website at ir.olema.com.

Olema Oncology reported its Q1 2025 financial results and operational progress. The company ended Q1 with $392.7 million in cash and a net loss of $30.4 million. Key developments include:

The company's lead drug palazestrant showed promising results in Phase 1b/2 study, achieving 13.8 months median progression-free survival in combination with ribociclib for ER+/HER2- metastatic breast cancer patients. Two pivotal Phase 3 trials are advancing: OPERA-01 (monotherapy) with top-line data expected in 2026, and OPERA-02 (combination therapy) set to begin in 2025.

Additionally, Olema presented preclinical data for OP-3136, demonstrating anti-tumor activity in ovarian, non-small cell lung, and prostate cancer models. The Phase 1 trial for OP-3136 continues patient enrollment.